Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
The emergence of new infections in India is a growing concern
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Subscribe To Our Newsletter & Stay Updated
